 Shares of Revance Therapeutics Inc. RVNC, 0.66 plummeted 34.7 toward an 18-month low in premarket Monday, which puts them on track for a record one-day selloff, after the company said the the Food and Drug Administration issued a Complete Response Letter CRL regarding the biotechnology companys treatment of glabellar, or frown, lines. The company said late Friday that FDA determined it could not approve the Biologics License Application BLA for DaxibotulinumtoxinA for Injection in its present form, citing deficiencies related to an inspection of Revances manufacturing facility. 